Ironwood Pharmaceuticals IRWD
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$3.75M (4 inflow days, 16 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 34.0% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 10.93% to 8.99% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| O'Shaughnessy Asset Management, LLC | Mutual Fund | 2026/Q3 | +937,699 | 0.8% |
| BlackRock | Mutual Fund | 2026/Q3 | +686,889 | 11.2% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +659,731 | 0.4% |
| Ritholtz Wealth Management | Mutual Fund | 2026/Q3 | +470,997 | 0.5% |
| FMR | Mutual Fund | 2026/Q3 | +342,619 | 0.8% |
| Principal Global Investors, LLC | Mutual Fund | 2026/Q3 | +306,858 | 0.2% |
| LPL Financial LLC | Mutual Fund | 2026/Q3 | +280,240 | 0.2% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +264,298 | 0.8% |
| CWA Asset Management Group, LLC | Mutual Fund | 2026/Q3 | +208,277 | 0.3% |
| Legato Capital Management, LLC | Mutual Fund | 2026/Q3 | +180,409 | 0.1% |
| Focus Partners Wealth, LLC | Mutual Fund | 2026/Q3 | +167,692 | 0.1% |
| Virtus Investment Advisers, LLC | Mutual Fund | 2026/Q3 | +143,181 | 0.3% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +313,518 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +4,425,627 | 10.8% |
| Mackenzie Financial Corporation | Mutual Fund | 2026/Q3 | +1,807,459 | 1.4% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 15 Nov 2026 | Tammi Gaskins | Senior Vice President & Chief Commercial Officer | Intent to Sell (Form 144) | -6,666 | $4.85 | – |
| 23 Sep 2026 | Michael Shetzline | Former Chief Medical Officer, Senior VP and Head of Research & Drug Development | Intent to Sell (Form 144) | -83,306 | $4.53 | – |
| 14 Sep 2026 | Alexander Denner | Independent Director | Other Acquisition | +3,694 | – | 327,549 |
| 19 Jul 2026 | Jeffrey Silber | Chief Medical Officer, Head of Research & Drug Development | Other Acquisition | +137,036 | – | 137,036 |
| 6 Jul 2026 | Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Automatic Disposition | -127,890 | $4.52 | 2,235 |
| 15 Jun 2026 | Jay Shepard | Independent Director | Other Acquisition | +63,481 | – | 235,036 |
| 15 Jun 2026 | Mark Currie | Independent Director | Other Acquisition | +63,481 | – | 676,900 |
| 15 Jun 2026 | Catherine Moukheibir | Independent Director | Other Acquisition | +63,481 | – | 181,425 |
| 15 Jun 2026 | Julie McHugh | Independent Chairperson | Other Acquisition | +63,481 | – | 250,749 |
| 15 Jun 2026 | Julie McHugh | Independent Chairperson | Automatic Disposition | -21,571 | $3.73 | 250,749 |
| 15 Jun 2026 | Marla Kessler | Independent Director | Other Acquisition | +63,481 | – | 229,364 |
| 15 Jun 2026 | Jon Duane | Independent Director | Other Acquisition | +63,481 | – | 253,820 |
| 15 Jun 2026 | Alexander Denner | Independent Director | Other Acquisition | +67,546 | – | 323,855 |
| 18 May 2026 | Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Other Acquisition | +25,000 | – | 311,445 |
| 16 Mar 2026 | Sarissa Capital Management LP | Open Market Disposition | -6,730,800 | $3.31 | 9,188,635 | |
| 12 Mar 2026 | Alexander Denner | Independent Director | Other Acquisition | +4,451 | – | 256,309 |
| 9 Mar 2026 | Thomas McCourt | Chief Executive Officer | Other Acquisition | +409,836 | – | 1,038,128 |
| 9 Mar 2026 | Michael Shetzline | Former Chief Medical Officer, Senior VP and Head of Research & Drug Development | Other Acquisition | +136,612 | – | 281,293 |
| 9 Mar 2026 | Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Other Acquisition | +163,934 | – | 286,445 |
| 9 Mar 2026 | John Minardo | Chief Legal Officer | Other Acquisition | +136,612 | – | 271,868 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 14,860,120 | 9.0% | 9.8 |
| 15 Oct 2026 | 15,887,553 | 9.6% | 8.0 |
| 30 Sep 2026 | 15,567,942 | 9.4% | 6.2 |
| 15 Sep 2026 | 18,728,986 | 11.3% | 13.1 |
| 31 Aug 2026 | 17,654,677 | 10.7% | 11.9 |
| 14 Aug 2026 | 18,066,382 | 10.9% | 6.4 |
No comments yet — be the first to weigh in on IRWD.
Sign in to join the discussion.